Early use of an anti-inflammatory agent to improve prognosis in Covid-19 patients |
Editorial
eMediNexus Coverage from: 
Early use of an anti-inflammatory agent to improve prognosis in Covid-19 patients

6 Read Comments                

The hallmark of Covid-19 is a hyperinflammatory response characterised by raised inflammatory markers (C-reactive protein, ferritin and D-dimers) and inflammatory cytokines and increased neutrophil-to-lymphocyte ratio. And, if this inflammatory response continues unabated, it can even be life-threatening. Hence, controlling this inflammatory response is key to improving prognosis.Hospitalized covid-19 patients have a more aggressive inflammatory response than patients being treated at home. The ...
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now